Related Experiment Video
Updated: Jan 25, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Histologic Remission in Ulcerative Colitis: Are We There Yet?
Millie D Long1, David T Rubin2
1Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Inflammatory Bowel Diseases Center, Chapel Hill, NC, USA.
Histologic remission is crucial for ulcerative colitis treatment, but more research is needed before it can be a standard endpoint. Current data show it improves outcomes, yet its role requires further investigation.
Area of Science:
- Gastroenterology
- Inflammatory Bowel Disease Research
- Clinical Trial Analysis
Background:
- The evolving landscape of inflammatory bowel disease (IBD) management emphasizes achieving treatment targets, including mucosal healing.
- Defining "mucosal healing" requires evaluating the role of "histologic" remission in ulcerative colitis (UC).
Discussion:
- This systematic review and meta-analysis examines histologic healing rates associated with medical therapies for UC within randomized controlled trials (RCTs).
- While observational studies consistently link histologic remission to better patient outcomes, its definitive inclusion as a management endpoint is premature.
Key Insights:
- Histologic remission is associated with improved outcomes in ulcerative colitis.
- Current evidence from RCTs on histologic healing rates for UC therapies is being synthesized.
- Further research is necessary to validate histologic remission as a reliable endpoint for UC management.
Outlook:
- Future research should focus on standardizing histologic assessment and confirming its predictive value in diverse UC populations.
- The development of robust criteria for histologic remission is essential for its adoption as a clinical endpoint.
- Continued investigation is vital to refine treatment strategies and outcome definitions in IBD.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Stomach Histology
Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
Histology of the Large Intestine
The innermost mucosa layer comprises simple columnar epithelium, lamina propria, and muscularis mucosae. This layer is primarily populated with absorptive cells, tasked with water absorption, and goblet cells, responsible for secreting mucus to...